T-621
Not Specified (Neurodegenerative, Metabolic, Muscle, Aging-related)
Pre-clinicalActive
Key Facts
Indication
Not Specified (Neurodegenerative, Metabolic, Muscle, Aging-related)
Phase
Pre-clinical
Status
Active
Company
About Endurance Bio
Endurance Bio is an early-stage biotech targeting the fundamental biology of aging and disease by enhancing mitochondrial and lysosomal function. The company's pipeline is led by T-168, a candidate ready for Phase 2 trials in ALS, Parkinson's, and Alzheimer's disease, with notable inclusion in an externally funded Parkinson's trial in Norway. With a second asset, T-621, in IND-enabling studies, the company is positioning itself in the high-need, high-value space of neurodegenerative and age-related diseases, backed by a lean team and key scientific advisors.
View full company profile